

CORRECTION

Open Access

Correction to: Role of Bruton's tyrosine kinase in B cells and malignancies



Simar Pal Singh^{1,2,3}, Floris Dammeijer^{1,3,4} and Rudi W. Hendriks^{1*}

Correction to: Mol Cancer

<https://doi.org/10.1186/s12943-018-0779-z>

Following publication of the original article [1], the authors reported an error in Table 1. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row). The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.

Author details

¹Department of Pulmonary Medicine, Room Ee2251a, Erasmus MC Rotterdam, PO Box 2040, NL 3000, CA, Rotterdam, The Netherlands.

²Department of Immunology, Rotterdam, The Netherlands. ³Post graduate school Molecular Medicine, Rotterdam, The Netherlands. ⁴Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.

Published online: 03 April 2019

Reference

1. Singh PS, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. *Mol Cancer*. 2018;17:57 <https://doi.org/10.1186/s12943-018-0779-z>.

* Correspondence: r.hendriks@erasmusmc.nl

¹Department of Pulmonary Medicine, Room Ee2251a, Erasmus MC Rotterdam, PO Box 2040, NL 3000, CA, Rotterdam, The Netherlands
Full list of author information is available at the end of the article



Table 1 Clinical trials with BTK inhibitors in B cell malignancies

Patient population	Therapeutic regimen	Phase	Efficacy	Ref
R/R CLL	Ibrutinib	Ib/II	ORR (71%), PR (20%)	[11]
R/R CLL	Ibrutinib	III	ORR (63%)	[248]
TN CLL	Ibrutinib	Ib/II	ORR (85%), CR (26%)	[199]
TN CLL	Ibrutinib	III	ORR (86%), CR (4%)	[13]
R/R MCL	Ibrutinib	II	ORR (68%), CR (21%)	[187]
R/R MCL	Ibrutinib	III	ORR (72%), CR (19%)	[249]
R/R WM	Ibrutinib	II	ORR (91%), Major response (73%)	[188]
R/R ABC-DLBCL	Ibrutinib	II	ORR (37%)	[196]
R/R CLL	Ibrutinib-Rituximab	II	ORR (95%), CR (8%)	[250]
R/R CLL	Ibrutinib-bendamustine-rituximab	III	ORR (83%), CR (10%)	[251]
R/R MCL	Ibrutinib-Rituximab	II	ORR (88%), CR (44%), PR (44%)	[252]
R/R CLL	Acalabrutinib	I/II	ORR (95%)	[12]
R/R	Acalabrutinib	II	ORR (81%), CR (40%), PR (41%)	[219]
R/R CLL	ONO/GS-4059	I	ORR (96%)	[222]
R/R MCL	ONO/GS-4059	I	ORR (92%)	[222]
R/R non-GCB DLBCL	ONO/GS-4059	I	ORR (35%)	[222]
R/R CLL	BGB-3111	I	ORR (90%)	[221, 253]
R/R MCL	BGB-3111	I	ORR (80%)	[253]
R/R MZL	Ibrutinib	II	ORR (51%)	[254]
R/R FL	Ibrutinib	I	ORR (38%)	[186]

CLL Chronic Lymphocytic leukemia, MCL Mantle cell lymphoma, WM Waldenström's Macroglobulinemia, ABC-DLBCL Activated B-cell Diffuse large B cell Lymphoma, MZL Marginal zone lymphoma, FL Follicular lymphoma, R/R relapsed or refractory, TN treatment-naïve, ORR overall response rate, CR complete response, PR partial response, Major response: complete response or at least 50% reduction in serum IgM levels